Request submitted to FDA to change the location of the treatment sessions from the Medical University of South Carolina (MUSC) to Dr. Mithoefer’s office. We propose renting a “crash cart” …
It’s my pleasure to report some excellent news. About 10 AM, Friday, November 2, FDA contacted me to say that MAPS’ MDMA/PTSD protocol was approved. This approval marks the culmination of 16 …
MAPS submitted to the FDA today the protocol for Dr. Michael Mithoefer and Dr. Mark Wagner’s MAPS-supported pilot study into the use of MDMA-assisted psychotherapy in the treatment of patients who …
As part of its submission to FDA of a protocol designed to study the use of MDMA in the treatment of PTSD, MAPS’ commissioned an extensive review of the scientific literature on MDMA. This literature …
A draft of the MDMA/PTSD protocol that MAPS has been working for 2 years to develop, with Dr. Michael Mithoefer and Mark Wagner, Ph.D., at the Medical University of South Carolina, has now been posted …
The US Sentencing Commission held an open hearing concerning its proposal to increase penalties on MDMA. Testimony about MDMA opposing the increase was presented by Rick Doblin, Ph.D., David Nichols, Ph.D., …
MAPS convened a protocol design meeting in San Francisco to discuss the details of a protocol evaluating the use of MDMA-assisted psychotherapy in the treatment of Post-Traumatic Stress Disorder (PTSD). …
Rick Doblin outlines MAPS’ strategy for the development of the therapeutic use of MDMA into an FDA-approved prescription medicine, at the State of Ecstasy conference in San Francisco, sponsored by …
Teleconference with the FDA concerning MDMA psychotherapy research to treat anxiety, depression and pain in cancer patients, the FDA indicates a willingness to approve a “proof of principle” …
